GlassScriptPhysician profile
Umer H Siddiqui
NPI 1245251321
$138,677.83
in general payments reported to CMS, 2019-2025
33 companies · $8,895 in 2025
The $8,895 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $22K · 2021: $11K · 2022: $13K · 2023: $10K · 2024: $10K · 2025: $8,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $4,728 · Travel and Lodging: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,396.50 |
| Food and Beverage | $4,728.14 |
| Travel and Lodging | $1,270.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56,964.98 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Sunovion Pharmaceuticals INC. | $48,917.36 | 2019-2020 | |
| Mylan Specialty L.P. | $28,175.73 | 2019-2024 | Yupelri, Yupelri |
| Glaxosmithkline, LLC. | $2,253.79 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.37 | 2019-2025 | Ofev |
| Electromed, INC. | $220.89 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $189.48 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $183.51 | 2021-2025 | Dupixent |
| Genzyme Corporation | $157.51 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $144.10 | 2021-2022 | |
| Philips North America LLC | $100.17 | 2019-2024 | (8874) Incourage |
| United Therapeutics Corporation | $95.66 | 2021-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $93.19 | 2019-2024 | Arikayce |
| Grifols USA, LLC | $87.83 | 2023-2025 | Prolastin-C Liquid |
| Amgen INC. | $84.89 | 2024-2025 | Tezspire, Tavneos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.17 | 2024-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $70.98 | 2021 | |
| Paratek Pharmaceuticals, INC. | $70.65 | 2023-2024 | Nuzyra |
| Harmony Biosciences LLC | $57.31 | 2021-2025 | |
| Fisher & Paykel Healthcare INC | $46.01 | 2020-2025 | Fisher & Paykel Healthcare |
| Avadel Cns Pharmaceuticals, LLC | $43.93 | 2024-2025 | Lumryz |
| Resmed Corp | $34.39 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $27.96 | 2021-2022 | |
| Baxter Healthcare | $25.16 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $24.02 | 2025 | Zepbound |
| Pulmonx Corporation | $21.29 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Viatris Specialty LLC | $18.93 | 2025 | Yupelri |
| Tactile Systems Technology INC | $16.87 | 2024 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2022 | |
| Inspire Medical Systems, INC. | $13.73 | 2024 | Inspire |
| Verona Pharma, INC. | $13.62 | 2025 | Ohtuvayre |
| Ambu INC. | $12.43 | 2021 | |
| Itamar Medical INC | $9.69 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.